These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14499309)

  • 21. Niacin skin test response in dyslexia.
    Cyhlarova E; Montgomery P; Ross MA; Richardson AJ
    Prostaglandins Leukot Essent Fatty Acids; 2007 Aug; 77(2):123-8. PubMed ID: 17890071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.
    Messamore E; Hoffman WF; Janowsky A
    Schizophr Res; 2003 Aug; 62(3):251-8. PubMed ID: 12837522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosomal fragile site expression in Turkish psychiatric patients.
    Taştemir D; Demirhan O; Sertdemir Y
    Psychiatry Res; 2006 Nov; 144(2-3):197-203. PubMed ID: 17007939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bipolar disorder not otherwise specified in relation to the bipolar spectrum.
    Bader CD; Dunner DL
    Bipolar Disord; 2007 Dec; 9(8):860-7. PubMed ID: 18076535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.
    Miller CL; Llenos IC; Dulay JR; Weis S
    Brain Res; 2006 Feb; 1073-1074():25-37. PubMed ID: 16448631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and neuropsychological correlates of insight in schizophrenia and bipolar I disorder: does diagnosis matter?
    Varga M; Magnusson A; Flekkøy K; David AS; Opjordsmoen S
    Compr Psychiatry; 2007; 48(6):583-91. PubMed ID: 17954145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder.
    Ishikawa M; Mizukami K; Iwakiri M; Asada T
    Neurosci Lett; 2005 Aug; 383(3):272-7. PubMed ID: 15955420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia.
    Webster MJ; O'Grady J; Kleinman JE; Weickert CS
    Neuroscience; 2005; 133(2):453-61. PubMed ID: 15885920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid.
    Morrow JD; Minton TA; Awad JA; Roberts LJ
    Arch Dermatol; 1994 Nov; 130(11):1408-12. PubMed ID: 7979442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of serum from bipolar versus schizophrenic patients on spontaneous acetylcholine release at mammalian neuromuscular junction.
    Veggetti MI; De Lorenzo S; Cassone JJ; Losavio AS; Muchnik S
    Clin Neurophysiol; 2006 Dec; 117(12):2645-52. PubMed ID: 17011822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
    Kilbourne AM; Brar JS; Drayer RA; Xu X; Post EP
    Psychosomatics; 2007; 48(5):412-7. PubMed ID: 17878500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.
    Smesny S; Rosburg T; Baur K; Rudolph N; Sauer H
    Neuropsychopharmacology; 2007 Oct; 32(10):2067-73. PubMed ID: 17314920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal dysfunctions in schizophrenia.
    Balogh Z; Benedek G; Kéri S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):297-300. PubMed ID: 17889979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia.
    Glahn DC; Barrett J; Bearden CE; Mintz J; Green MF; Serap Monkul E; Najt P; Soares JC; Velligan DI
    Psychol Med; 2006 Aug; 36(8):1085-95. PubMed ID: 16734948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics influencing age at onset in psychotic disorders.
    Ongür D; Lin L; Cohen BM
    Compr Psychiatry; 2009; 50(1):13-9. PubMed ID: 19059508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls.
    Nilsson BM; Hultman CM; Wiesel FA
    Prostaglandins Leukot Essent Fatty Acids; 2006 May; 74(5):339-46. PubMed ID: 16600583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorder.
    Gupta S; Steinmeyer CH; Lockwood K; Lentz B; Schultz K
    Am J Geriatr Psychiatry; 2007 Jul; 15(7):627-33. PubMed ID: 17586787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.
    Morrow JD; Awad JA; Oates JA; Roberts LJ
    J Invest Dermatol; 1992 May; 98(5):812-5. PubMed ID: 1373750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes.
    Papolos D; Mattis S; Golshan S; Molay F
    J Affect Disord; 2009 Nov; 118(1-3):28-38. PubMed ID: 19631388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.